ArticleBMC research notes2026
Anticancer proteasome inhibitors are detrimental to the growth of Toxoplasma gondii in vitro.
Article in BMC research notes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveToxoplasma gondii is a globally widespread intracellular protozoan that infects an estimated 25% of the world's human population. There is currently no cure for chronic toxoplasmosis, and treatments for acute infection often cause harmful side effects. Here, we used well-established growth assays to evaluate the anti-toxoplasmic effects of three FDA-approved anticancer proteasome inhibitors, bortezomib, carfilzomib, and ixazomib, on Toxoplasma growth in vitro.
resultsWe found that treatment of Toxoplasma with bortezomib, carfilzomib, and ixazomib inhibits parasite growth with IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.